Paragraph | Jotup

EQS-News: REPLY: The Board of Directors approved the draft financial statements for the year 2023

Retrieved on:

Wednesday, April 10, 2024

Automation, EXM, EUR, COVID, Paragraph, Growth, Intelligence, Internet, Artificial intelligence, STAR, AI, MTA, Insurance, Reply, Cloud computing, Cryptocurrency

Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2023, which will be submitted for approval to the Shareholders’ Meeting to be held on first call in Turin on 23 April 2024.

Key Points:

Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2023, which will be submitted for approval to the Shareholders’ Meeting to be held on first call in Turin on 23 April 2024.
The Reply Group closed 2023 with a consolidated turnover of €2,118.0 million, an increase of 12.0% compared to €1.891.1 million in 2022.
As at 31 December 2023, the Group’s net financial position has been positive at €204.9 million (€70.6 million at 31 December 2022).
As at 30 September 2023, the net financial position was positive at €189.7 million.

Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchici

Retrieved on:

Wednesday, March 20, 2024

Paragraph, Gout, Vexatious litigation, Shanda, Chronic pain, Settlement, PALO, Justice, Takeda, License, FDA, Federal Trade Commission, Nursing

That litigation arose from Scilex’s filing of a sNDA with the FDA seeking to expand the label for its FDA-approved liquid colchicine product, Gloperba®, a preventive treatment for gout.

Key Points:

That litigation arose from Scilex’s filing of a sNDA with the FDA seeking to expand the label for its FDA-approved liquid colchicine product, Gloperba®, a preventive treatment for gout.
As part of the Settlement Agreement, the Scilex Parties entered into a License Agreement with Takeda granting the Company and its affiliates a non-exclusive license to certain patents owned by Takeda.
The Settlement Agreement is subject to approval by the district court, and by both the Federal Trade Commission and the U.S. Department of Justice, as is required in Paragraph IV patent case settlements.
For more information on Scilex Holding Company, refer to www.scilexholding.com .

REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 2023.

Retrieved on:

Wednesday, March 13, 2024

The Reply Group closed 2023 with a consolidated turnover of €2,118.0 million, an increase of 12.0% compared to €1.891.1 million in 2022.

Key Points:

The Reply Group closed 2023 with a consolidated turnover of €2,118.0 million, an increase of 12.0% compared to €1.891.1 million in 2022.
As at 31 December 2023, the Group’s net financial position has been positive at €204.9 million (€70.6 million at 31 December 2022).
As at 30 September 2023, the net financial position was positive at €189.7 million.
In a short time, we will be living in a union of automation, artificial intelligence, digital interfaces and connected objects.

Brevo Launches Customer Data Platform, Enhanced AI features and Mobile Push Notifications

Retrieved on:

Tuesday, February 13, 2024

Human voice, EST, Firefox, Behavior, CDP, Headline, Elevate, Paragraph, CRM, Creativity, CX

In addition, Brevo is announcing new AI functions, expanding capabilities to better understand customer habits and drive personalized multi-channel campaigns at scale.

Key Points:

In addition, Brevo is announcing new AI functions, expanding capabilities to better understand customer habits and drive personalized multi-channel campaigns at scale.
Many marketers rely on retargeting and legacy data management platforms based on segments fed with third-party data.
Brevo CDP unifies and manages customer data across the whole tech stack.
Using a new Push dashboard for Brevo segments and lists, Brevo customers can drive action and create a seamless customer experience from within the Brevo ecosystem.

Notice Regarding Commencement of Tender Offer for Benesse Holdings, Inc. (Securities Code: 9783) by Bloom 1 K.K.

Retrieved on:

Monday, January 29, 2024

Publishing, Communications, Other Education, Managed Care, Continuing, University, Preschool, Health, Primary, Secondary, Education, Financial instrument, Multimedia, Bloom, Tender, Paragraph, Graduation, Order

We hereby announce today that the attached press release issued by Bloom 1 K.K.

Key Points:

We hereby announce today that the attached press release issued by Bloom 1 K.K.
titled “Notice Regarding Commencement of Tender Offer for Benesse Holdings, Inc. (Securities Code: 9783)” has been released.
(the Offeror) to Benesse Holdings, Inc. (the Target Company of the Tender Offer).
Notice Regarding Commencement of Tender Offer for Benesse Holdings, Inc. (Securities Code: 9783) dated January 29, 2024
View source version on businesswire.com: https://www.businesswire.com/news/home/20240126441982/en/

Press release - Parliament concerned about the rule of law in Slovakia

Retrieved on:

Wednesday, January 17, 2024

Special, European Parliament, Legislation, Paragraph, Television, European, Corruption, Government, Language, Crime, Fraud, Environment, Parliament, General officer, Non-governmental organization, RTVS

Need to protect the rule of law

Key Points:

Need to protect the rule of law
MEPs are particularly concerned about the unjustified use of a fast-track procedure for the criminal code reform and the dissolution of the Special Prosecutor’s Office that handles corruption cases and serious crimes.
These changes threaten the integrity of judicial processes and undermine the EU’s fight against fraud according to MEPs.
MEPs stress that any criminal law reform must ensure the continuation of ongoing criminal cases and the effectiveness of new ones.
Parliament is very concerned by plans to adopt legislation undermining the civic space, restricting the work of NGOs and stigmatising organisations receiving foreign funding.

Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)

Retrieved on:

Thursday, January 11, 2024

Glomus tumor, Paragraph, Somatostatin, DOTA-TATE, Food, LNTH, FDA, Abbreviated New Drug Application, Certification

LUTATHERA® is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

Key Points:

LUTATHERA® is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.
Based on the most recent update to the FDA’s online paragraph IV database listings,1 Lantheus believes it is the first applicant to have filed a substantially complete ANDA for Lutetium Lu 177 Dotatate containing a Paragraph IV certification under the provisions of the Hatch-Waxman Act.
Should its ANDA be approved by the FDA, Lantheus believes it will be eligible for 180 days of generic marketing exclusivity in the U.S.
Lantheus licensed exclusive worldwide commercialization rights (excluding certain Asian territories) to 177Lu-PNT2003 from POINT Biopharma Global, Inc. in December of 2022.
To read the press release announcing that licensing transaction, please click here .

Update on Disclosed Matter: Mitsubishi Electric’s Execution of the Company-split Agreement to Transfer Automotive-equipment Business to Newly Incorporated Subsidiary as Part of Restructuring

Retrieved on:

Wednesday, November 15, 2023

Automotive, Automotive Manufacturing, Technology, EV, Electric Vehicles, Manufacturing, Hardware, Transfer, Yaskawa Electric Corporation, Companies Act, Paragraph, Update, Executive, Part, Mitsubishi Electric

Mitsubishi Electric Corporation (TOKYO:6503) announced today that it has executed a Company-split agreement and formally established a wholly owned subsidiary, Melco Automotive Equipment Business Split Preparation Corporation, in line with the previous announcement “(Update on Disclosed Matter) Mitsubishi Electric to Transfer Automotive-equipment Business to New Subsidiary as Part of Restructuring” issued on October 31.

Key Points:

Mitsubishi Electric Corporation (TOKYO:6503) announced today that it has executed a Company-split agreement and formally established a wholly owned subsidiary, Melco Automotive Equipment Business Split Preparation Corporation, in line with the previous announcement “(Update on Disclosed Matter) Mitsubishi Electric to Transfer Automotive-equipment Business to New Subsidiary as Part of Restructuring” issued on October 31.
Item numbers below are consistent with the previous announcement on October 31, 2023, and newly announced information is underlined.
The Company Split is a simplified absorption-type company split, pursuant to Article 784, Paragraph 2 of the Companies Act of Japan, and Mitsubishi Electric therefore does not require approval of this at a shareholders’ meeting.
Accordingly, the Company Split will be implemented on the decision of the President and CEO, with due consideration of deliberations at the Executive Officers’ Meeting.

REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 2023.

Retrieved on:

Tuesday, November 14, 2023

Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2023.

Key Points:

Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2023.
As of September 2022, EBITDA was €218.6 million (€207.6 million should be considered for comparison purposes)*.
As at 30 September 2023, the Group’s net financial position was positive at €189.7 million.
The net financial position as at 30 June 2023 was positive for €101.6 million.

Defendant Angie Wong whistleblower faces multiple lawsuits, and a court order in Georgia, says Stan Fitzgerald, Legacy PAC founder and L-Strategies partner

Retrieved on:

Friday, December 8, 2023

The litigation, Plaintiff L-Strategies, LLC v. Defendant Angie Wong (aka Angie Wong Sie Ying), has been filed with the Clerk of Superior Court, Coweta County, Georgia, Docket SUV2023000784 on June 30, 2023, 04:23 PM.

Key Points:

The litigation, Plaintiff L-Strategies, LLC v. Defendant Angie Wong (aka Angie Wong Sie Ying), has been filed with the Clerk of Superior Court, Coweta County, Georgia, Docket SUV2023000784 on June 30, 2023, 04:23 PM.
In a second filing, Legacy PAC Partners Stan Fitzgerald and Jared Craig filed a 272,500.00 lawsuit against Angie Wong for Tortious Interference with Business, Defamation/Libel, Conversion/Trover in August 2023.
The Litigation America First Legacy PAC filed a petition against former President Angie Wong.
Notwithstanding, Wong continued to appear on television and radio shows bearing the misrepresentation that she was the President of Legacy PAC.